Abstract
Lip et al (Stroke 2010;41:2731–2738, PMID 20966417) evaluated predictors of thromboembolic risk in an anticoagulated atrial fibrillation (AF) clinical trial cohort of 7,329 patients. The predictive value of the CHADS2, Framingham, NICE 2006, ACC/AHA/ESC, ACCP, and CHADS-VASc risk stratification schemes were tested. The CHADS-VASc score (P <.0001) had the highest hazard ratio (3.75) among the tested schemes. The negative predictive value for CHADS-VASc was 99.5%. Coronary artery disease and smoking were additional risk factors, whereas alcohol use appeared protective. The authors conclude that among risk stratification schemes, the CHADS-VASc scheme correctly identified the greatest proportion of AF patients at high risk for stroke.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
